At OXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. We are currently recruiting for a Senior Director, Head of Global Reward to join the HR team. The purpose of this role is Act as a key member of the HR Leadership Team (HRLT), leading the Company’s Reward initiatives, working with the Chief People Officer to provide thought leadership and expertise to help the Company develop and implement a clear, meaningful and motivating remuneration strategy that plays a key role in supporting how we attract, retain and grow talent globally across the OXB Group. Responsible for informing key decision-making and adopting a global mindsight to strengthen the Company’s purpose-driven, high-performing culture. Your responsibilities in this role would be: • To research, identify, develop and gain approval for remuneration strategies which address the business needs for all levels of the company and to develop implementation plans which are then delivered in the appropriate timeframe within the business. • Develop a robust governance structure for all reward processes and policies • Provide expert advice to the leadership and annual remuneration processes ensuring the processes are fair and equitable and in line with the reward strategy. This will include supporting the CPO with preparation for RemCom. • Manage the day-to-day operations of the Group’s share plans (RSU, SAYE, LTIP) including review of the share plans and the administration of those plans • Coordinate, communicate and manage the annual award and vesting process for the share plans globally • Maintain a good understanding of the external market and innovative compensation and benefits being offered by leading employers • Define clear job families, market data and comparators in order to run cyclical internal and external benchmarking • To develop the links between performance and reward and ensure that individual performance and company performance are reflected appropriately in reward structures and strategy • Manage the annual salary review and bonus scheme processes in line with existing timescales • Develop and present proposals to strengthen our benefits offerings with a specific D&I lens and market-led solutions • In collaboration with the VP HR, create a promotion and internal movement framework that provides career pathway opportunities and will inform decision-making in relation to remuneration • Run ad-hoc remuneration projects • Ensure that all pay and benefit offers are clearly communicated and well understood by employees to play a key role in the retention of talent. • To develop and manage specialist reward supplier relationships associated with the supply of consultancy or products and services provided within the business and act as Prime point of contact for those relationships • To work closely with HR business partners and business leaders to ensure reward strategies meet the needs of employees, managers and leaders. • To provide education to the business on all aspects of reward processes and improve visibility and understanding of the value of the total reward packages. We are looking for: • Equivalent of a minimum of degree level knowledge • Seasoned HR professional with significant experience at a senior level in strategy development and operational leadership, translating strategy into operational plans. Strong knowledge and experience in principles, practices and functions of HR leadership • Strong Reward background with experience of all areas on compensation and benefits including share plan management • In-depth knowledge and experience of internal controls best practice applicable to new initiatives identified for implementation • Knowledge and experience of global pay regulations • Knowledge and experience of leading global mobility and international assignments About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. Why Join Us? • Competitive total reward packages • Wellbeing programmes that support your mental and physical health • Career development opportunities to help you grow and thrive • Supportive, inclusive, and collaborative culture • State-of-the-art labs and manufacturing facilities • A company that lives its values: Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At OXB, we’re future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Collaborate. Contribute. Change lives. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.